Hemispherx BioPharma, Inc (NYSE:HEB) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 645,892 shares, a decline of 6.5% from the April 28th total of 690,823 shares. Based on an average daily trading volume, of 163,594 shares, the days-to-cover ratio is presently 3.9 days. Currently, 2.6% of the company’s stock are short sold.

In other news, CEO Thomas K. Equels purchased 200,000 shares of the stock in a transaction that occurred on Tuesday, April 11th. The stock was acquired at an average price of $0.50 per share, with a total value of $100,000.00. Following the purchase, the chief executive officer now owns 420,455 shares in the company, valued at approximately $210,227.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas K. Equels purchased 72,464 shares of the stock in a transaction that occurred on Thursday, April 27th. The stock was purchased at an average cost of $0.69 per share, with a total value of $50,000.16. Following the purchase, the chief executive officer now owns 492,919 shares in the company, valued at approximately $340,114.11. The disclosure for this purchase can be found here. In the last three months, insiders purchased 296,274 shares of company stock valued at $165,000.

Shares of Hemispherx BioPharma (NYSE:HEB) opened at 0.55 on Thursday. Hemispherx BioPharma has a 12 month low of $0.39 and a 12 month high of $2.64. The company’s market cap is $14.40 million. The firm’s 50-day moving average price is $0.60 and its 200-day moving average price is $0.65.

TRADEMARK VIOLATION NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/05/25/short-interest-in-hemispherx-biopharma-inc-heb-drops-by-6-5.html.

Hemispherx BioPharma Company Profile

Hemispherx Biopharma, Inc (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company’s segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon.

12 Month Chart for NYSE:HEB

Receive News & Ratings for Hemispherx BioPharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.